WAYNE, PA — Teleflex Incorporated (NYSE: TFX) has announced the recent completion of its acquisition of substantially all of BIOTRONIK SE & Co. KG’s Vascular Intervention business. The €760 million deal, finalized earlier than anticipated, significantly expands Teleflex’s portfolio of interventional access products and strengthens its global reach in the growing peripheral intervention market.
“We are pleased to announce the completion of the acquisition of substantially all of the Vascular Intervention business of BIOTRONIK earlier than expected,” said Liam Kelly, Chairman, President, and CEO of Teleflex. “The acquisition will significantly enhance our global presence in the cath lab, expand our suite of innovative technologies, and improve patient care.”
The acquisition includes BIOTRONIK’s comprehensive portfolio for coronary and peripheral interventions. Key coronary products include the Pantera™ Lux™ Drug-Coated Balloon Catheter, the PK Papyrus™ Covered Coronary Stent for acute arterial perforations, and the Orsiro™ Mission Drug Eluting Stent, known for its ultrathin design and clinical performance. Peripheral products added to Teleflex’s lineup feature the Passeo™-18 Lux™ Peripheral Drug-Coated Balloon Catheter, the Dynetic™-35 Balloon-Expandable Cobalt Chromium Stent, and the Pulsar™-18 T3 Self-Expanding Stent.
The acquisition also positions Teleflex to further invest in Freesolve™, a sirolimus-eluting Resorbable Metallic Scaffold (RMS) technology. Freesolve™, which received CE Mark approval in 2024, is designed to provide temporary scaffolding with drug delivery for de novo coronary artery lesions. Teleflex plans to initiate a U.S. pivotal study for the technology, which has demonstrated promising results in European trials, including resorption after 12 months and competitive efficacy compared to drug-eluting stents.
“This acquisition allows us to position this advanced coronary portfolio alongside our existing Interventional business and establish our global footprint in the fast-growing peripheral intervention market,” Kelly added. “The acquired business is rooted in robust research and development, clinical expertise, and global manufacturing capabilities, which we believe will further bolster Teleflex’s innovation pipeline, and position the company to participate in the emerging potential for resorbable scaffold technologies.”
Financial Outlook
Teleflex anticipates that the acquired Vascular Intervention business will contribute €177 million ($204 million) in revenue during the second half of 2025, with €91 million ($105 million) expected in the fourth quarter alone. Beginning in 2026, the portfolio is projected to deliver annual revenue growth of 6% or more, with adjusted earnings per share forecasted to see $0.10 accretion in the first year of ownership, becoming increasingly accretive thereafter.
With the integration into Teleflex’s operations underway, this acquisition heralds a new chapter for the company as it continues its mission to expand access to groundbreaking interventional technologies and improve patient outcomes globally.
For the latest news on everything happening in Chester County and the surrounding area, be sure to follow MyChesCo on Google News and MSN.